LONDON (Reuters) – The UK drug regulator has advised people with significant allergic reactions not to receive the Pfizer-Biontec COVID-19 vaccine. The -19 vaccine is seen before being administered on December 8, 2020 at the Royal Victoria Hospital in Belfast, Northern Ireland. Liam McBurney / Pool via REUTERS began mass vaccinating its people on Tuesday. This is one of the biggest logistics challenges in the global movement, starting with older and leading workers in the history of peace, said Stephen Bowis, medical director of the National Health Service, who changed the advice after two NHS workers reported receiving anaphylactoid reactions related to vaccination. “People with a history of significant significant allergic reactions to the precaution that those with a significant history of allergic reactions will not receive this vaccine after two, as advised by the MHRA (regulator) as is common in newer vaccines, have responded poorly yesterday,” Bowis said. The MHRA said it was seeking more information, and that Pfizer and Bioendech supported the MHRA’s investigation. The Drugs and Health Products Regulatory Agency (MHRA) first approved the vaccine, developed by Germany’s Bioendech and Pfizer last week, while the US Food and Drug Administration (FDA) and the European Pharmaceuticals Agency (EMA). A) Continue to evaluate the data. “Last evening, we saw two case reports of allergic reactions. We know from a very detailed medical examination that this is not a feature, ”MHRA CEO June Rain told lawmakers. Pfizer claims that people with a history of severe adverse allergic reactions are excluded from their postoperative trials. The FDA released the documents in preparation for an advisory panel meeting on Tuesday that said it had met its expectations for the effectiveness and safety data recognition of the Pfizer vaccine. The summary document stated that 0.63% of the vaccine group and 0.51% of the placebo group recorded allergic reactions in the trials. , Peter Openshaw, professor of experimental medicine at Imperial College London, said the number was very low. “This monitoring shows that we know quickly about these two allergic reactions and that the monitor works well when the controller acts on it to provide precautionary advice,” he said. Alistair Smout Report; Additional report by Josephine Mason, Ludwig Burger and Patricia Weiss, editing by Paul Sandil and Alexandra Hudson.
Source
